Study immune patterns during guselkumab skin response in psoriasis
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial studies how the immune system changes in the skin after guselkumab treatment for psoriasis, including the scalp. You may be asked to meet certain scalp severity and medication safety rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have psoriasis affecting the scalp with a severity score (PSSI) of at least 12
- You are not taking medicines that suppress the immune system within the last 4 weeks
- You are not pregnant and you are not breastfeeding
- You do not have a serious immune system weakness or known severe immunodeficiency
- You do not have tuberculosis or any active serious infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study tests whether a higher dose of guselkumab (a biologic medicine) given less frequently works as well as the standard dose for treating moderate-to-severe plaque psoriasis. The goal is to find a dosing schedule that is both effective and convenient for patients.
This study looks at immune system differences in people with moderate-to-severe psoriasis. It aims to help guide more precise (targeted) treatment choices and may improve how well treatment works for you.
This study is testing a medicine called guselkumab (Tremfya) for people with psoriasis who are already taking another biologic medicine, ustekinumab, but need to switch. The goal is to see how well guselkumab works in real-world use.
This study follows people with psoriatic arthritis (joint pain and swelling linked to psoriasis) who are starting a newer medication called guselkumab. Researchers want to learn how long patients continue taking this medicine and how well it works for them.
This trial tests if guselkumab, a drug given as an injection under the skin, can help people with psoriatic arthritis (PsA) who haven't had enough relief from standard treatments. It aims to find a new option for managing joint pain and swelling.
Hear when a new Psoriasis of Scalp trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.